HOME >> MEDICINE >> NEWS
Still no effective treatment for post-lyme disease symptoms

DENVER, CO While Lyme disease is usually cured with antibiotic treatment, some patients experience persistent fatigue and cognitive dysfunction. In a study presented at the annual meeting of the American Academy of Neurology, researchers share their experience in a study evaluating ceftriaxone, a broad spectrum antibiotic they hoped would be effective in treating post-Lyme disease symptoms.

In a double blind, single center, randomized clinical trial, 55 Lyme disease patients with persistent severe fatigue were randomly assigned to receive the ceftriaxone or a placebo. Although patients assigned to ceftriaxone showed significant improvement in fatigue compared to the placebo group, seven percent were hospitalized with adverse treatment effects, according to study author Lauren Krupp, MD, of State University of New York -- Stony Brook.

We had hoped to find a treatment option for these patients that would improve their symptoms and reduce the level of infection, comments Krupp. But given these adverse effects, and because neither cognitive functioning nor laboratory measure of infection were improved, our study does not support the use of repeated courses of ceftriaxone.

Krupp added, The observation that fatigue did improve is very encouraging and hopefully other treatment approaches that are better tolerated or safer for patients can be identified to ameliorate post-Lyme disease symptoms.


'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
18-Apr-2002


Page: 1

Related medicine news :

1. Still time to apply for the $10,000 Maxwell A. Pollack Award!
2. Still mulling over last nights argument? It could affect your heart
3. Strategy effective against drug resistant tuberculosis
4. Study shows patch therapy may be as effective as oral medications
5. Chronic pain treatments more effective when taken together, new study shows
6. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
7. Costs of antidepressants could have funded effective alternatives
8. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
9. Government wasting your taxpayer money on ineffective drug cure
10. Neurobehavioral function during coma, stroke rehabilitation effective for elderly
11. European folic acid policies are not effective enough

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Still effective treatment for post lyme disease symptoms

(Date:5/18/2013)... few extra cups of coffee each month might help ... as primary sclerosing cholangitis (PSC), a new study suggests. ... found that drinking coffee was associated with a reduced ... cirrhosis of the liver, liver failure and biliary cancer. ... "While rare, PSC has extremely detrimental effects," ...
(Date:5/18/2013)... 18, 2013) There are significant cost and ... to diagnose or treat gastrointestinal problems, according to ... , A study by New York Presbyterian Hospital ... testing may substantially reduce the cost and risk ... is believed to affect nearly 25 percent of ...
(Date:5/18/2013)... 2013 Assisted living and retirement ... safety and comfort of their residents. Systems Technologies ... with an effective and cost-efficient solution – VisionLink ... integrated, turnkey communications solution that helps nurses provide ... independence and privacy. , The VisionLink ...
(Date:5/18/2013)... 2013 Transvaginal mesh lawsuits ... move forward in a consolidated litigation underway in New ... According to a notice on the Court’s website, the ... litigation will be held on Wednesday, May 22nd. ... in the proceeding on behalf of women who suffered ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
Cached News: